This project will fund the purchase of a high-throughput real-time PCR instrument that will allow to us to achieve two scientific goals:
i) expand the ongoing projects on AD biomarker genetics to a large, newly recruited cohort of dementia patients and healthy controls for whom both CSF biomarker data (i.e. levels of Aβ, Aβ42, tau, phospho-tau proteins) and DNA samples are already available, and
ii) perform targeted, high-throughput microRNA (miRNA) and messenger RNA (mRNA) profiling in human brain samples to extend our laboratory’s work on mapping the functional basis of disease-associated sequence variants. Both projects are tightly linked and will likely provide essential information for future AD biomarker studies.